Form D · Biotechnology
Ray Therapeutics, Inc.
San Francisco, CA · CIK 0001920476
Offering snapshot reported May 26, 2023 · SEC filing
- Reported sold
- $14M Offering amount: $100M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 15, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 26, 2023 | Initial | $13,999,986 | No comparison | 13 | SEC filing |
| Apr 5, 2022 | Initial | $6,000,000 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-482772
Source: Form D, filed May 26, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gary Abrams | Director |
| Sean Ainsworth | Director, Executive |
| Tiba Aynechi | Director |
| Paul Bresge | Director, Executive |
| Raymond Camahort | Director |
| Hannah Chang | Director |
| Cameron Gallagher | Director |
| Andrew Howard | Executive |
| Dmitry Kuzmin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Sansome Street, Suite 3500
San Francisco, CA, 94104
San Francisco, CA, 94104